Emerging Therapies for Glioblastoma
Cancers, ISSN: 2072-6694, Vol: 16, Issue: 8
2024
- 5Citations
- 51Usage
- 53Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations5
- Citation Indexes5
- Usage51
- Downloads32
- Abstract Views19
- Captures53
- Readers53
- 53
- Mentions1
- News Mentions1
- News1
Most Recent News
University of Texas Rio Grande Valley Researcher Focuses on Cancer Gene Therapy (Emerging Therapies for Glioblastoma)
2024 APR 25 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Gene Therapy Daily -- Fresh data on cancer gene therapy are presented
Review Description
Glioblastoma is most commonly a primary brain tumor and the utmost malignant one, with a survival rate of approximately 12–18 months. Glioblastoma is highly heterogeneous, demonstrating that different types of cells from the same tumor can manifest distinct gene expression patterns and biological behaviors. Conventional therapies such as temozolomide, radiation, and surgery have limitations. As of now, there is no cure for glioblastoma. Alternative treatment methods to eradicate glioblastoma are discussed in this review, including targeted therapies to PI3K, NFKβ, JAK-STAT, CK2, WNT, NOTCH, Hedgehog, and TGFβ pathways. The highly novel application of oncolytic viruses and nanomaterials in combating glioblastoma are also discussed. Despite scores of clinical trials for glioblastoma, the prognosis remains poor. Progress in breaching the blood–brain barrier with nanomaterials and novel avenues for targeted and combination treatments hold promise for the future development of efficacious glioblastoma therapies.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85191559199&origin=inward; http://dx.doi.org/10.3390/cancers16081485; http://www.ncbi.nlm.nih.gov/pubmed/38672566; https://www.mdpi.com/2072-6694/16/8/1485; https://scholarworks.utrgv.edu/ibcs_fac/17; https://scholarworks.utrgv.edu/cgi/viewcontent.cgi?article=1016&context=ibcs_fac; https://dx.doi.org/10.3390/cancers16081485
MDPI AG
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know